<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02604680</url>
  </required_header>
  <id_info>
    <org_study_id>BLI1100-203</org_study_id>
    <nct_id>NCT02604680</nct_id>
  </id_info>
  <brief_title>A Safety and Efficacy Evaluation of Topical Treatments for Moderate-Severe Facial Acne Vulgaris</brief_title>
  <official_title>A Randomized, Controlled Evaluation of the Safety and Efficacy of Topical Treatments for Moderate-Severe Facial Acne Vulgaris</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Braintree Laboratories</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Braintree Laboratories</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the study is to compare the safety and efficacy of multiple formulations of
      BLI1100 to a control group and placebo in treating patients with moderate-severe acne
      vulgaris.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2015</start_date>
  <completion_date type="Actual">June 2016</completion_date>
  <primary_completion_date type="Actual">June 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Absolute change in total lesion count</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatment success based on Investigator Global Assessment</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">509</enrollment>
  <condition>Acne Vulgaris</condition>
  <arm_group>
    <arm_group_label>BLI1100-1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Topical gel</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BLI1100-2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Topical gel</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BLI1100-3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Topical gel</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BLI1100-4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Topical gel</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Topical gel</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BLI1100-1</intervention_name>
    <description>BLI1100-1 Topical gel</description>
    <arm_group_label>BLI1100-1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BLI1100-2</intervention_name>
    <description>BLI1100-2 Topical gel</description>
    <arm_group_label>BLI1100-2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BLI1100-3</intervention_name>
    <description>BLI1100-3 Topical gel</description>
    <arm_group_label>BLI1100-3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BLI1100-4</intervention_name>
    <description>BLI1100-4 Topical gel</description>
    <arm_group_label>BLI1100-4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo - Topical gel</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Males or females 12 to 45 years of age, inclusive, in good general health.

          2. Clinical diagnosis of facial acne vulgaris

          3. Patients with an Investigator's Global Assessment severity score of at least 3 that
             meet the following lesion count criteria:

               -  A minimum of 20 but not more than 50 inflammatory lesions (including the nose)

               -  A minimum of 30 but not more than 100 non-inflammatory lesions on the face
                  (including the nose)

               -  No nodules are allowed on the entire face.

          4. Each patient or parent/guardian will read and sign the consent form as required by IRB
             regulations. Patients under the age of 18, but of sufficient age to provide assent (as
             determined by IRB regulations), will complete an assent form.

          5. Female patients of childbearing potential must have a negative urine pregnancy test
             prior to receiving study medication.

          6. Treatment with estrogens, androgens, or anti-androgenic agents for a non-contraceptive
             indication must be stable for 6 months prior to the first dose of study product and
             remain unchanged during the study.

          7. Patients who are willing and able to follow all study procedures, attend all scheduled
             visits, and successfully complete the study.

          8. Patients who are mentally competent in the Investigator's judgment, to provide
             informed consent/assent to participate in the study

        Exclusion Criteria:

          1. Patients who had been treated with:

               -  systemic retinoids during a 6-month period before Visit 1 or by systemic
                  antibiotics during a 4-week period before Visit 1

               -  or by a topical treatment (eg, antibiotics, benzoyl peroxide, retinoids, azelaic
                  acid, resorcinol, salicylates, sulfacetamide sodium and derivatives, glycolic
                  acid, dapsone) or systemic corticosteroids during a 2-week period before the
                  first dose of study medication.

          2. History of hereditary angio-edema

          3. Pregnancy, lactation or patient, who is not practicing effective contraception.

          4. Any clinically relevant finding at their baseline physical examination or
             dermatological medical history such as severe systemic diseases or diseases of the
             facial skin.

          5. A known endocrine malfunction (hyperthyroidism, hypothyroidism, diabetes, adrenal
             insufficiency).

          6. Erythroderma, immunodeficiency disorders and Mycosis Fungoides

          7. History of Epilepsy or Parkinson's disease

          8. History of alcohol and/or drug abuse within 5 years of screening

          9. Facial hair (beard), excessive scarring, sunburn or other disfigurement that may
             obscure the accurate assessment of acne grade

         10. Any single facial skin condition assessment graded as &quot;Severe&quot; at Visit 1

         11. Using drugs known to be photosensitizers because of the possibility of increased
             phototoxicity.

         12. Refusal to cease using the following types of facial products: astringents, toners,
             abradants, facials, loofahs, peels containing glycolic or other acids, masks, washes
             or soaps containing benzoyl peroxide (BPO), hydroquinone, sulfacetamide sodium or
             salicylic acid, non-mild facial cleansers, or moisturizers that contain retinol,
             salicylic acid, or α- or β-hydroxy acids .

         13. Using medications that are reported to exacerbate acne .

         14. Have had a facial procedure (chemical or laser peel, microdermabrasion, artificial
             ultraviolet therapy) performed by an esthetician, beautician, physician, nurse, or
             other practitioner, during the 4 weeks prior to Visit 1.

         15. Unwilling to avoid excessive swimming and sun exposure to include artificial UV light
             exposure (tanning beds).

         16. Patients using comedogenic makeup.

         17. Have a known hypersensitivity or previous allergic reaction to any of the components .

         18. Employees of the clinical research site or organization involved in the study, or an
             immediate family member (partner, offspring, parents, siblings, or sibling's
             offspring) of an employee.

         19. Have a member of the same household in this trial.

         20. Patients who have participated in an investigational clinical, surgical, drug, or
             device study within the past 30 days

         21. Patients who, in the opinion of the investigator, should not be included in the study
             for any reason, including inability to follow study procedures

         22. Patients who withdraw consent before completion of Visit 1 procedures
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John McGowan</last_name>
    <role>Study Director</role>
    <affiliation>Braintree Laboratories, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>BLI Research Site 27</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BLI Research Site 24</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BLI Research Site 51</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85745</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BLI Research Site 40</name>
      <address>
        <city>Rogers</city>
        <state>Arkansas</state>
        <zip>72758</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BLI Research Site 57</name>
      <address>
        <city>Chula Vista</city>
        <state>California</state>
        <zip>91911</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BLI Research Site 56</name>
      <address>
        <city>Costa Mesa</city>
        <state>California</state>
        <zip>92626</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BLI Research Site 18</name>
      <address>
        <city>Encino</city>
        <state>California</state>
        <zip>91436</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BLI Research Site 7</name>
      <address>
        <city>Fremont</city>
        <state>California</state>
        <zip>94538</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BLI Research Site 45</name>
      <address>
        <city>Upland</city>
        <state>California</state>
        <zip>91786</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BLI Research Site 41</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80220</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BLI Research Site 39</name>
      <address>
        <city>Wheat Ridge</city>
        <state>Colorado</state>
        <zip>80033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BLI Research Site 19</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BLI Research Site 49</name>
      <address>
        <city>Jupiter</city>
        <state>Florida</state>
        <zip>33458</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BLI Research Site 54</name>
      <address>
        <city>Miami Lakes</city>
        <state>Florida</state>
        <zip>33016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BLI Research Site 12</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33126</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BLI Research Site 20</name>
      <address>
        <city>Ormond Beach</city>
        <state>Florida</state>
        <zip>32174</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BLI Research Site 59</name>
      <address>
        <city>Port Saint Lucie</city>
        <state>Florida</state>
        <zip>34984</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BLI Research Site 15</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33709</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BLI Research Site 1</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BLI Research Site 29</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BLI Research Site 28</name>
      <address>
        <city>Wellington</city>
        <state>Florida</state>
        <zip>33414</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BLI Research Site 43</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33406</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BLI Research Site 11</name>
      <address>
        <city>Plainfield</city>
        <state>Indiana</state>
        <zip>46168</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BLI Research Site 33</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BLI Research Site 34</name>
      <address>
        <city>Beverly</city>
        <state>Massachusetts</state>
        <zip>01915</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BLI Research Site 42</name>
      <address>
        <city>Quincy</city>
        <state>Massachusetts</state>
        <zip>02169</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BLI Research Site 37</name>
      <address>
        <city>Fort Gratiot</city>
        <state>Michigan</state>
        <zip>48059</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BLI Research Site 9</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BLI Research Site 47</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68144</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BLI Research Site 5</name>
      <address>
        <city>Newington</city>
        <state>New Hampshire</state>
        <zip>03801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BLI Research Site 46</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <zip>11790</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BLI Research Site 50</name>
      <address>
        <city>High Point</city>
        <state>North Carolina</state>
        <zip>27262</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BLI Research Site 52</name>
      <address>
        <city>Wilmington</city>
        <state>North Carolina</state>
        <zip>28401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BLI Research Site 32</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45255</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BLI Research Site 55</name>
      <address>
        <city>Norman</city>
        <state>Oklahoma</state>
        <zip>73071</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BLI Research Site 4</name>
      <address>
        <city>Gresham</city>
        <state>Oregon</state>
        <zip>97030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BLI Research Site 60</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BLI Research Site 10</name>
      <address>
        <city>Johnston</city>
        <state>Rhode Island</state>
        <zip>02919</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BLI Research Site 53</name>
      <address>
        <city>Goodlettsville</city>
        <state>Tennessee</state>
        <zip>37072</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BLI Research Site 58</name>
      <address>
        <city>Murfreesboro</city>
        <state>Tennessee</state>
        <zip>37130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BLI Research Site 14</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BLI Research Site 30</name>
      <address>
        <city>Beaumont</city>
        <state>Texas</state>
        <zip>77701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BLI Research Site 6</name>
      <address>
        <city>Bryan</city>
        <state>Texas</state>
        <zip>77802</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BLI Research Site 3</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77056</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BLI Research Site 8</name>
      <address>
        <city>New Braunfels</city>
        <state>Texas</state>
        <zip>78130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BLI Research Site 44</name>
      <address>
        <city>Pflugerville</city>
        <state>Texas</state>
        <zip>78660</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BLI Research Site 16</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78249</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BLI Research Site 21</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BLI Research Site 26</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BLI Research Site 25</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 12, 2015</study_first_submitted>
  <study_first_submitted_qc>November 12, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 13, 2015</study_first_posted>
  <disposition_first_submitted>July 25, 2017</disposition_first_submitted>
  <disposition_first_submitted_qc>July 27, 2017</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">July 28, 2017</disposition_first_posted>
  <last_update_submitted>July 27, 2017</last_update_submitted>
  <last_update_submitted_qc>July 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acne Vulgaris</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

